Free Trial

Zhengye Biotechnology (NASDAQ:ZYBT) Trading 5.3% Higher - Here's What Happened

Zhengye Biotechnology logo with Medical background

Key Points

  • Zhengye Biotechnology's share price increased by 5.3% to $8.42 during mid-day trading on Tuesday, despite a significant drop in trading volume.
  • Wall Street analysts have upgraded the stock to a "hold" rating, indicating a cautious optimism about its future performance.
  • Several large investors, including Geode Capital Management and Invesco Ltd., have recently purchased new stakes in Zhengye Biotechnology, signaling potential confidence from institutional investors.
  • Looking to export and analyze Zhengye Biotechnology data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT - Get Free Report) traded up 5.3% on Tuesday . The stock traded as high as $8.96 and last traded at $8.42. 44,872 shares traded hands during trading, a decline of 69% from the average session volume of 145,402 shares. The stock had previously closed at $8.00.

Wall Street Analyst Weigh In

Separately, Wall Street Zen upgraded shares of Zhengye Biotechnology to a "hold" rating in a report on Saturday, August 2nd.

View Our Latest Research Report on ZYBT

Zhengye Biotechnology Stock Up 5.5%

The company has a current ratio of 1.31, a quick ratio of 0.88 and a debt-to-equity ratio of 0.01. The firm's 50-day moving average price is $6.55 and its 200 day moving average price is $6.73.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Geode Capital Management LLC purchased a new stake in shares of Zhengye Biotechnology during the 2nd quarter valued at approximately $174,000. Invesco Ltd. bought a new position in shares of Zhengye Biotechnology in the 2nd quarter worth $220,000. Finally, Jane Street Group LLC purchased a new position in Zhengye Biotechnology in the 2nd quarter worth $1,158,000.

Zhengye Biotechnology Company Profile

(Get Free Report)

Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.

Recommended Stories

Should You Invest $1,000 in Zhengye Biotechnology Right Now?

Before you consider Zhengye Biotechnology, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zhengye Biotechnology wasn't on the list.

While Zhengye Biotechnology currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

$15 Billion for Cybersecurity: The Government’s Next Big Push
Tesla’s Future Unleashed: Elon’s Robotics Move Changes Everything
Top Trades: Massive Gains and Costly Mistakes to Avoid

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines